18th Febuary 2013
I believe Health-care business are resilence in nature. Below listed Health-care stocks for a general comparison:
Cordlife - 68 cents
PE around 15
PB about 2
Revenue growth about 20%. Profit about 50%
Net profit margin = 34%
Â
IHH - $1.335
PE about 70
PB 0.6
Revenue growth - not consistence
Net profit margin = 11%
Pacific Healthcare - 7.5 cents
PE - making lost
PB about 3.5
Growth - Negative
Q & M 32.5 cents
PE more than 30
PB more than 6
Revenue growth about 20%. Profit about 10%
Net profit margin about 10%
Raffles Mediccal $3.15
PE more than 30
PB more than 4
Revenue growth about 10%. Profit about 10%.
Net profit margin less than 20%
CORDLIFE clearly top the lists in term of growth, profit margin & best of all yield. Using PE as a comparison it's the cheapest.
I am revisiting the above Healthcare stocks posted on 18th February 2013
9th September 2013
Cordlife - $1.33 – increased by 92%
Profit growth by 95%
PE = 23
IHH - $1.56 – increased by 18%
Profit drop by 4%
Pacific Healthcare 7.5c – drop by 33%
Profit lost from $2.5 millions to $4.26 millions
Q & M - 30c – drop by 8%
Profit drop by 9%
Raffles Medical – fall by 4%
Profit increased by 16%
Cordlife best performance share price increased by 92% over 7 months
Going forward I still belief CORLIFE will still outperformance all these stocks again.
11/9/2013 - Maybank KE Research on Cordlife:-
Recommendation: Buy
Target Price: $1.44
Cordlife CEO Jeremy Yee bought another 20,000 shares on 13th September 2013. His total holding increased from 1,711,034 to 1,731,034 shares. Since early this month he had bought 80,000 shares.
Maybank Kim Eng said in a report in early July 2013 that Cordlife had an "overwhelming" 72 percent market share in Singapore and the entry of a new competitor, a joint venture between AsiaMedic Ltd and Cryoviva International, was not a threat to the company.
Cordlife announced Private Placement of an Aggregate of up to 26,838,000 New Ordinary Shares in the Capital of the Company (the Placement Shares) comprising (I) Placement via a Placement Agent and (II) Placement via Direct Subscriptions by Investors, at S$1.25 for each Placement Share (the Issue Price) to Raise Gross Proceeds of up to S$33,547,500.
Rationale of this placement & use of proceeds is to support future growth of the group & working capital.
4th October 2013 - Am Fraser Research on Cordlife:-
Recommendation: Hold
Target Price: $1.35
FIL Ltd on 3rd October 2013 bought 53,000 Cordlife shares @ $1.34. This raised its holding from 22,226,000 shares (9.56%) to 22,279,000 shares (9.58%).
Today Cordlife share price corrected down to $1,18 and with regard to it's recent private placement @ $1.25.
At this price I belive the down-side is limited and present a good opportunity to accumulate Cordlife shares.
